PBAC's latest decision on Pralatrexate: Recommended with restriction (2017). Considered for Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in adult patients who have progressed after at least one prior therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$45k/QALY
$15k/QALY–$45k/QALY · across 3 submissions
Submissions
4
first 2015
Submissions
4
2015 → 2017
Eligible population
Adults with relapsed or refractory peripheral T-cell lymphoma who have progressed after at least one prior therapy
Therapy area
Oncology
Line of therapy
Second-line
Evidence base
Single-arm
Primary endpoint
OS
Pivotal trial size
115 patients
Key trials
PDX-008
Comparator
basket of comparators (chemotherapy regimens)
Economic model
CUA
ICER basis
Range aggregates 3 submissions (2016–2017) — not a single base case.
Submission history
Nov 2015: Not recommended · Authority Required
Mar 2016: Not recommended · Authority Required — ICER $75k/QALY